Abstract:Background Lung metastasis is the leading cause of death in patients with osteosarcoma (OS), and new drugs are urgently needed. Epigenetic reprogramming is a recently proposed hallmark of malignancy; therefore, targeting epigenetic enzymes might provide a novel therapeutic strategy for OS lung metastasis. We recently reported that ailanthone (AIL), a natural product isolated from the Chinese medicinal plant Ailanthus altissima, inhibits OS cell growth and induces substantial metabolic changes; however, its direct targets remain unclear. Purpose To identify the direct targets of AIL in OS and to explore the effects of AIL on OS lung metastasis in vivo. Study design Direct target proteins of AIL and downstream signaling pathways were identified in Saos-2 and U-2OS OS cells. The in vivo effects of AIL on OS lung metastasis were investigated using a mouse model. Methods A novel surface plasmon resonance-high-performance liquid chromatography-mass spectrometry (SPR-HPLC-MS) assay was used to determine direct targets of AIL in OS. A cellular thermal shift assay, molecular docking analysis, enzyme activity assay, qRT-PCR, western blotting, chromatin immunoprecipitation assay, and reverse tests were performed to confirm the target and downstream pathway of AIL. A tumor xenograft model was used to verify the efficacy and mechanisms in vivo. Results Histone-lysine N-methyltransferase 2A (KMT2A) together with its scaffold protein menin (MEN1) were identified as direct target proteins of AIL in OS. AIL induced the autophagic degradation of the KMT2A-MEN1 complex. Moreover, AIL inhibited intracellular H3K4 methyltransferase activity and epigenetically inhibited the transcription of genes in the serine biosynthetic pathway (SSP). Furthermore, AIL suppressed OS lung metastasis and downregulated KMT2A, MEN1, and SSP in mouse models. Conclusion This work showed that AIL targets the KMT2A-MEN1 complex and inhibits SSP to suppress OS lung metastasis. Notably, AIL exhibits new mechanisms of action, distinct from those of existing anti-OS drugs. On the basis of these findings, we proposed a novel strategy to treat OS by targeting epigenetic enzymes and cancer metabolism.

Wogonoside Impedes the Progression of Acute Myeloid Leukemia Through Inhibiting Bone Marrow Angiogenesis.

Wogonoside Exerts Anti-Leukemia of AML Cells Via Restricting Phospholipid Scramblase 1 Gene Expression and Promoting Its Translocation into Nuclear

Wogonoside Induces Cell Cycle Arrest And Differentiation By Affecting Expression And Subcellular Localization Of Plscr1 In Aml Cells

Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells

Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.

Wogonoside Inhibits Angiogenesis in Breast Cancer Via Suppressing Wnt/β‐catenin Pathway

Wogonin Inhibits Angiogenesis Via a C-Myc/hif-1α–dependent Pathway in Multiple Myeloma

On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation

Effect of Magnetic Nanoparticles on Apoptosis and Cell Cycle Induced by Wogonin in Raji Cells

PLSCR1/IP3R1/Ca2+ Axis Contributes to Differentiation of Primary AML Cells Induced by Wogonoside.

Wogonin, a Natural and Biologically-active Flavonoid, Influences a Murine WEHI-3 Leukemia Model in Vivo Through Enhancing Populations of T- and B-Cells

Wogonin Inhibits Tumor Angiogenesis Via Degradation of HIF-1α Protein.

Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment

Wogonoside Induces Depalmitoylation and Translocation of PLSCR1 and N-RAS in Primary Acute Myeloid Leukaemia Cells.

Wogonoside Exerts Growth-Suppressive Effects Against T Acute Lymphoblastic Leukemia Through the STAT3 Pathway

Wogonin Inhibits WEHI‐3 Leukemia Cells in Blab/C Mice in Vivo

Wogonin Suppresses Human Alveolar Adenocarcinoma Cell A549 Migration in Inflammatory Microenvironment by Modulating the IL‐6/STAT3 Signaling Pathway

Wogonoside induces autophagy in MDA-MB-231 cells by regulating MAPK-mTOR pathway

Wogonin Suppresses Tumor Growth in Vivo and VEGF-induced Angiogenesis Through Inhibiting Tyrosine Phosphorylation of VEGFR2.

Ailanthone Targets the KMT2A-MEN1 Complex to Suppress Lung Metastasis of Osteosarcoma

Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-κB signaling